Navigation Links
Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
Date:12/2/2008

ng-term value.

The Company's commercialization strategy for all PharmFilm(R) products is to partner with the innovator or other specialty pharma or leading consumer products companies who have the core competency to sell-in and manage the sales and marketing of the products. For the Company's existing and future partners, PharmFilm(R) formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm(R) is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and ODTs.

SafeHarbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2007, in Item 1A of the Company's subsequent Quarterly Reports on Form 10-Q, in other of the Company's filings with the SEC from time to time, including Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
2. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
3. Introducing Strativa Pharmaceuticals
4. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
5. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
11. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly traded ... development, sales and marketing of premium branded highly ... it is awarding exclusive Vestiage territories in the ... Illuminating Facial Care. Qualified applicants can request an ... to info(at)vestiageinc(dot)com and putting RELUMA in the "Subject" ...
(Date:5/23/2013)... 2013  BioScrip, Inc. (NASDAQ: BIOS ) ... Jefferies 2013 Global Healthcare Conference to be held June ... Richard Smith , President and ... , Chief Financial Officer, will present on Monday, June ... About BioScrip BioScrip, Inc. provides comprehensive ...
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan Racing ... cord blood stem cell banking and therapeutics, announced today ... No. 16 Acorn Stairlifts Indy car driven by ... remainder of the IZOD IndyCar 2013 season.   ... work to support awareness of umbilical cord blood banking ...
(Date:5/23/2013)... May 23, 2013 Virobay, Inc. today announced ... has reached an important milestone, as Virobay has now ... a selective cathepsin S inhibitor.   The ... randomized, placebo-controlled study designed to evaluate the safety, tolerability, ... healthy adults. "The initiation of this Phase ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... by the National Nanotechnology Initiative (NNI) and the Oregon ... landscape of regional, state, and local (RSL) nanotechnology initiatives. ... visits on April 30 Where: Portland, Oregon ... Street, Portland, OR Who: Leaders of regional, ...
... PML Consortium, an association of pharmaceutical and biotechnology companies, ... from BioFortis to share and manage data relating to ... adverse event. Progressive multifocal leukoencephalopathy (PML) is ... immunocompromised patients. PML has been identified as a known ...
... about the disease and its overall occurrence and progression ... market. This is being exacerbated by the limited availability ... need for innovative and enhanced therapeutic and diagnostic tools ... treatment options. New analysis from Frost & ...
Cached Biology Technology:Registration now open: 2012 Regional, State, and Local Initiatives in Nanotechnology 2Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities 2European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 2European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 3
(Date:5/23/2013)... School of Public Health at Emory University, along ... have received a $4 million grant over four ... University (Health and Exposome Research Center: Understanding Lifetime ... grant awarded in the United States. , ... Institute of Environmental Health Sciences (NIEHS) of the ...
(Date:5/23/2013)... wrapping of genomic DNA around nucleosomes in the ... A team of Ludwig-Maximilians-Universitaet (LMU) in Munich now ... be locally displaced from nucleosomes for transcription. , ... in the cell nucleus, wrapped around disk-shaped particles ... four different histone proteins and accommodating two loops ...
(Date:5/23/2013)... Some prostate cancer patients unnecessarily undergo surgery or ... differences between slow-growing and aggressive forms of the ... Johns Hopkins Medical Institutes are developing technology that ... opt for relatively mild treatments or take drastic ... Anant Madabhushi, an associate professor of biomedical engineering ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Biochemistry: Unspooling DNA from nucleosomal disks 2Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... State University have essentially "cured" laboratory mice of mild, ... enzyme. The findings could offer a new approach ... could be identified that would do the same thing, ... Increased levels of this enzyme, called fatty acid ...
... mechanism for regulating viruses that has worked its way ... between adult and fetal hemoglobin production, Medical College of ... key to more targeted therapies for sickle cell patients ... oxygen throughout the body. Fetal hemoglobin, on the ...
... Malolactic fermentation is a key part in the process ... a common component in fruit, undergoes a chemical transformation, ... natural cider (unlike with wine), after this process there ... that the lactic bacteria become the dominant microbiota. Some ...
Cached Biology News:Discovery points to new approach for diabetes therapy 2Modulator of fetal hemoglobin switch may target sickle cell disease 2Modulator of fetal hemoglobin switch may target sickle cell disease 3Thesis analyzes factors responsible for the case of Basque natural cider turning bitter 2
... an intracellular marker normally present at high ... of bone marrow prelymphocytes. Elevated levels of ... cells are found to be associated with ... TdT thus provides a useful adjunct in ...
Request Info...
... RapidStak is a fast and ... Its high capacity and reliable ... confident walk away time than typical ... of set-up make for a seamless ...
... Interacting Protein/PBIP1 (phospho T78) ( Abpromise ... Antigen: Synthetic peptide: ... of Human MLF1 Interacting Protein ... 359815 Swiss Protein ...
Biology Products: